Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes

Luca Ronconi, Donatella Aldinucci, Q. Ping Dou, Dolores Fregona

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.

Original languageEnglish
Pages (from-to)283-292
Number of pages10
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume10
Issue number4
Publication statusPublished - May 2010

Fingerprint

Gold
Antineoplastic Agents
Cisplatin
Clinical Trials
Pharmacology
Kidney
Research
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • Anticancer drug
  • Dithiocarbamate
  • Gold compounds
  • Metallodrug
  • Nephrotoxicity
  • Proteasome inhibitor
  • Reactive oxygen species (ROS)
  • Thioredoxin reductase (TrxR)

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. / Ronconi, Luca; Aldinucci, Donatella; Dou, Q. Ping; Fregona, Dolores.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 10, No. 4, 05.2010, p. 283-292.

Research output: Contribution to journalArticle

@article{5b2217ee864e4d568b291658f0e6c611,
title = "Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes",
abstract = "In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.",
keywords = "Anticancer drug, Dithiocarbamate, Gold compounds, Metallodrug, Nephrotoxicity, Proteasome inhibitor, Reactive oxygen species (ROS), Thioredoxin reductase (TrxR)",
author = "Luca Ronconi and Donatella Aldinucci and Dou, {Q. Ping} and Dolores Fregona",
year = "2010",
month = "5",
language = "English",
volume = "10",
pages = "283--292",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes

AU - Ronconi, Luca

AU - Aldinucci, Donatella

AU - Dou, Q. Ping

AU - Fregona, Dolores

PY - 2010/5

Y1 - 2010/5

N2 - In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.

AB - In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.

KW - Anticancer drug

KW - Dithiocarbamate

KW - Gold compounds

KW - Metallodrug

KW - Nephrotoxicity

KW - Proteasome inhibitor

KW - Reactive oxygen species (ROS)

KW - Thioredoxin reductase (TrxR)

UR - http://www.scopus.com/inward/record.url?scp=77951660776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951660776&partnerID=8YFLogxK

M3 - Article

C2 - 20184554

AN - SCOPUS:77951660776

VL - 10

SP - 283

EP - 292

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 4

ER -